See the rest here: Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress...
See the rest here: Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress...
See the rest here: NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
Read the original post: Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral...
See the original post here: Spectral AI’s DeepView SnapShot® Wound Imaging System, Achieves UKCA Mark and FDA Class 1 Medical Device Classification
Here is the original post: Ayala Pharmaceuticals Announces Closing of Merger with Biosight
95%) in the second year post-administration]]>
Read the rest here: Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
See the original post here: Lirum Therapeutics to Present at the 2023 ThinkEquity Conference
Read more from the original source: GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
Recent Comments